Neural Autoantibody Prevalence in New-onset Focal Seizures of Unknown Etiology
Recruiting · NCT06388161 · Observational (researchers observe without assigning treatment) · Lead sponsor: Shen Chun-Hong
View the official record on ClinicalTrials.gov →What this trial is about
Seizure is one of the most common symptoms in autoimmune encephalitis with neuronal surface-mediated antibodies. Interestingly, some patients may exhibit new-onset seizures as the initial manifestation without fulminant sign of encephalitis, particularly in the early stage. It is essential to recognize these patients early and to perform antibody testing, as studies have reported early immunotherapy can improve their clinical outcomes. At the same time, it is important to limit the number of patients who require testing, for the sake of specificity and cost effectiveness. Thus, this prospective, multicenter study aims to identify neural antibodies in patients with focal seizures of unknown etiology, and to create a score to preselect patients requiring autoantibody testing.
Who can take part
Inclusion criteria
- Patients have a diagnosis of new-onset focal epileptic seizure or epilepsy and present with their first seizure within the previous 12 months
- Patients are prospectively recruited from the routine practice of epileptologists in epilepsy centers and epilepsy clinics
- There is no obvious suspicion of autoimmune encephalitis
- Written informed consent and sera are obtained
- Cerebrospinal fluid test must be conducted, when patients have detectable serum autoantibodies
Exclusion criteria
- Patients have other etiology of seizures, such as structure, infection, genetics and metabolism.
- Written informed consent are not obtained
- Loss of follow-up
Where it is running
1 location listed.
- 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China - Hangzhou, Zhejiang, China